Perspectives on challenges and opportunities for birth defects surveillance programs during and after the COVID-19 era.

In recent months, various public health measures have been implemented throughout the world in response to the coronavirus disease 2019 (COVID-19) pandemic. This outbreak, and the subsequent containment policies, may have a range of potential short- and long-term impacts on the monitoring and surveillance of other conditions, such as birth defects. In this commentary, we provide a perspective on these potential impacts on birth defects surveillance and analysis.

We discuss possible effects on clinical birth defect diagnoses, routine birth defects surveillance system activities, and epidemiologic considerations, as well as opportunities for mitigating the impact of COVID-19. Like many other sectors of public health and medicine, birth defects surveillance programs may be faced with organizational and methodological obstacles in the wake of a changing landscape.

VX-661
A2664-10 10 mg
EUR 224
Description: VX-661, one of vertex derivatives, corrects F508del-CFTR trafficking and increases F508del-CFTR protein activity in vitro [1]. VX-661 treated alone or in combination with ivacaftor have shown to enhance F508del-CFTR traf?cking to the cell surface. VX-661 has been at phase 2 study [1].

VX-661
A2664-5 5 mg
EUR 166
Description: VX-661, one of vertex derivatives, corrects F508del-CFTR trafficking and increases F508del-CFTR protein activity in vitro [1]. VX-661 treated alone or in combination with ivacaftor have shown to enhance F508del-CFTR traf?cking to the cell surface. VX-661 has been at phase 2 study [1].

VX-661
A2664-5.1 10 mM (in 1mL DMSO)
EUR 183
Description: VX-661, one of vertex derivatives, corrects F508del-CFTR trafficking and increases F508del-CFTR protein activity in vitro [1]. VX-661 treated alone or in combination with ivacaftor have shown to enhance F508del-CFTR traf?cking to the cell surface. VX-661 has been at phase 2 study [1].

VX-661
A2664-50 50 mg
EUR 560
Description: VX-661, one of vertex derivatives, corrects F508del-CFTR trafficking and increases F508del-CFTR protein activity in vitro [1]. VX-661 treated alone or in combination with ivacaftor have shown to enhance F508del-CFTR traf?cking to the cell surface. VX-661 has been at phase 2 study [1].

miRZip-661 anti-miR-661 microRNA construct
MZIP661-PA-1 Bacterial Streak
EUR 684
  • Category: MicroRNA Tools

hsa-miR-661 Primers
MPH01964 150 ul / 10 uM
EUR 121

p24-HIV(p24/661) Antibody
BNC610661-100 100uL
EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF660R conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC610661-500 500uL
EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF660R conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC400661-100 100uL
EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF640R conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC400661-500 500uL
EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF640R conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC430661-100 100uL
EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF543 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC430661-500 500uL
EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF543 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC470661-100 100uL
EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF647 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC470661-500 500uL
EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF647 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC550661-100 100uL
EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF555 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC550661-500 500uL
EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF555 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC040661-100 100uL
EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF405S conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC040661-500 500uL
EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF405S conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC050661-100 100uL
EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF405M conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC050661-500 500uL
EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF405M conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC680661-100 100uL
EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF568 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC680661-500 500uL
EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF568 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNUM0661-50 50uL
EUR 395
Description: Primary antibody against p24-HIV(p24/661), 1mg/mL

p24-HIV(p24/661) Antibody
BNC700661-100 100uL
EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF770 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC700661-500 500uL
EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF770 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC940661-100 100uL
EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF594 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC940661-500 500uL
EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF594 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNCH0661-100 100uL
EUR 199
Description: Primary antibody against p24-HIV(p24/661), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNCH0661-500 500uL
EUR 544
Description: Primary antibody against p24-HIV(p24/661), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC800661-100 100uL
EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF680 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC800661-500 500uL
EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF680 conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC810661-100 100uL
EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF680R conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC810661-500 500uL
EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF680R conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNCP0661-250 250uL
EUR 383
Description: Primary antibody against p24-HIV(p24/661), PerCP conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNCR0661-250 250uL
EUR 383
Description: Primary antibody against p24-HIV(p24/661), RPE conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNCA0661-250 250uL
EUR 383
Description: Primary antibody against p24-HIV(p24/661), APC conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNCAP0661-100 100uL
EUR 199
Description: Primary antibody against p24-HIV(p24/661), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNCAP0661-500 500uL
EUR 544
Description: Primary antibody against p24-HIV(p24/661), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNCB0661-100 100uL
EUR 199
Description: Primary antibody against p24-HIV(p24/661), Biotin conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNCB0661-500 500uL
EUR 544
Description: Primary antibody against p24-HIV(p24/661), Biotin conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC880661-100 100uL
EUR 199
Description: Primary antibody against p24-HIV(p24/661), CF488A conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNC880661-500 500uL
EUR 544
Description: Primary antibody against p24-HIV(p24/661), CF488A conjugate, Concentration: 0.1mg/mL

p24-HIV(p24/661) Antibody
BNUB0661-100 100uL
EUR 209
Description: Primary antibody against p24-HIV(p24/661), Concentration: 0.2mg/mL

p24-HIV(p24/661) Antibody
BNUB0661-500 500uL
EUR 458
Description: Primary antibody against p24-HIV(p24/661), Concentration: 0.2mg/mL

hsa-miR-661 miRNA Inhibitor
MIH03370 2 x 5.0 nmol
EUR 176

hsa-miR-661 miRNA Antagomir
MNH03370 2 x 5.0 nmol
EUR 329

Recombinant (E.Coli) Protein Kinase A Inactive holoenzyme type 1 alpha
RP-661 1 ug
EUR 164

Polyclonal MYOM2 / Myomesin 2 Antibody (aa612-661)
APR03243G 0.05ml
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human MYOM2 / Myomesin 2 (aa612-661). This antibody is tested and proven to work in the following applications:

MAP Kinase Substrate; EGF-R (661-681)
5-01501 4 x 1mg Ask for price

Human pre-microRNA Expression Construct Lenti-miR-661
PMIRH661PA-1 Bacterial Streak
EUR 684
  • Category: MicroRNA Tools

Recombinant Pichia pastoris SNX4 Protein (aa 1-661)
VAng-Cr6678-inquire inquire Ask for price
Description: Pichia pastoris Sorting nexin-4 (SNX4), recombinant protein.

Recombinant Clostridium Tetani uvrB Protein (aa 1-661)
VAng-Lsx01835-inquire inquire Ask for price
Description: Clostridium Tetani UvrABC system protein B, recombinant protein.

Recombinant Mycobacterium Tuberculosis Rv0102 Protein (aa 1-661)
VAng-Yyj0176-1mgEcoli 1 mg (E. coli)
EUR 6731
Description: Mycobacterium Tuberculosis Uncharacterized protein Rv0102/MT0111 (Rv0102, MT0111), recombinant protein.

Recombinant Treponema Pallidum tkt Protein (aa 1-661)
VAng-Cr0963-inquire inquire Ask for price
Description: Treponema Pallidum (strain Nichols) transketolase (tkt), recombinant protein.

Recombinant Brucella Abortus bhuA Protein (aa 1-661)
VAng-Lsx5157-inquire inquire Ask for price
Description: Brucella Abortus biovar 1 (strain 9-941) Heme transporter BhuA, recombinant protein.

Recombinant Brucella Suis bhuA Protein (aa 1-661)
VAng-Lsx5721-inquire inquire Ask for price
Description: Brucella Suis biovar 1 (strain 1330) Heme transporter BhuA, recombinant protein.

Recombinant Clostridium Difficile fbp Protein (aa 1-661)
VAng-Lsx9156-inquire inquire Ask for price
Description: Clostridium Difficile (strain 630) Fructose-1,6-bisphosphatase class 3, recombinant protein.

Recombinant HCV-1c E2 Protein (aa 384-661) [His]
VAng-Wyb7362-100g 100 µg
EUR 1747
Description: Hepatitis C virus (serotype 1c,isolate HC-G9) E2 protein, recombinant protein.

Recombinant HCV-1c E2 Protein (aa 384-661) [His]
VAng-Wyb7362-20g 20 µg
EUR 679
Description: Hepatitis C virus (serotype 1c,isolate HC-G9) E2 protein, recombinant protein.

Recombinant HCV-1c E2 Protein (aa 384-661) [His]
VAng-Wyb7362-50g 50 µg
EUR 1213
Description: Hepatitis C virus (serotype 1c,isolate HC-G9) E2 protein, recombinant protein.

Recombinant Trypanosoma Brucei HSP70-4 Protein (aa 1-661)
VAng-Wyb8104-inquire inquire Ask for price
Description: Trypanosoma Brucei brucei Heat shock 70 kDa protein 4, partial, recombinant protein.

Recombinant Caenorhabditis Elegans lst-2 Protein (aa 1-661)
VAng-Ly3528-inquire inquire Ask for price
Description: Caenorhabditis Elegans lateral signaling target protein 2 (lst-2), partial, recombination protein.

Anti-AFP (Tacatuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC
ADC-W-661 1mg Ask for price
Description: This ADC product is comprised of an anti-AFP monoclonal antibody conjugated via a MC-Vc-PAB-DMEA-(PEG2) linker to duocarmycin SA

Anti-Hu CD84 Purified
11-661-C025 0.025 mg
EUR 99

Anti-Hu CD84 Purified
11-661-C100 0.1 mg
EUR 158

Anti-Hu CD84 Purified Low Endotoxin
12-661-C100 0.1 mg
EUR 158

Anti-Hu CD84 APC
1A-661-T025 25 tests
EUR 140

Anti-Hu CD84 APC
1A-661-T100 100 tests
EUR 240

Anti-Hu CD84 FITC
1F-661-T025 25 tests
EUR 122

Anti-Hu CD84 FITC
1F-661-T100 100 tests
EUR 204

Anti-Hu CD84 PE
1P-661-T025 25 tests
EUR 140

Anti-Hu CD84 PE
1P-661-T100 100 tests
EUR 240

HIV type 1 Glycoprotein 140 (aa 37 - 661)(Du151) [His]
DAG2131 100 µg Ask for price

Recombinant Brucella Abortus bhuA Protein (strain 2308) (aa 1-661)
VAng-Lsx4953-inquire inquire Ask for price
Description: Brucella Abortus (strain 2308) Heme transporter BhuA, recombinant protein.

MAP Kinase Substrate; EGF-R (661-681) (AA: Lys-Arg-Glu-Leu-Val-Glu-Pro-Leu-Thr-Pro-Ser-Gly-Glu-Ala-Pro-Asn-Gln-Ala-Leu-Leu-Arg) (MW: 2318.66)
SP-101475-1 1 mg
EUR 164

A better understanding of these potential challenges faced by birth defects surveillance programs could facilitate better planning and collaboration across programs to overcome barriers to core activities and to prepare for novel opportunities for research and prevention.